[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade",
    "summary": "Eli Lilly (LLY) concluded the recent trading session at $796.03, signifying a -0.44% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=dbd3c27dde133afa7ddfea00ca95c72cd37440a33a6db63ba22b8fc58620ec07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733957121,
      "headline": "Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade",
      "id": 131941688,
      "image": "https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) concluded the recent trading session at $796.03, signifying a -0.44% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=dbd3c27dde133afa7ddfea00ca95c72cd37440a33a6db63ba22b8fc58620ec07"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900",
    "summary": "We recently published a list of Jim Cramer’s Latest Calls: Top 10 Stocks. In this article, we are going to take a look at where Eli Lilly And Co (NYSE:LLY) stands against other stocks highlighted in Jim Cramer’s latest calls. Jim Cramer in a recent program talked about Bitcoin and reminded investors that he has […]",
    "url": "https://finnhub.io/api/news?id=fb894cf526206c9268a058014151289ebb260ad7ca553539da921376e35a4fbb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733941145,
      "headline": "Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900",
      "id": 131941428,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer’s Latest Calls: Top 10 Stocks. In this article, we are going to take a look at where Eli Lilly And Co (NYSE:LLY) stands against other stocks highlighted in Jim Cramer’s latest calls. Jim Cramer in a recent program talked about Bitcoin and reminded investors that he has […]",
      "url": "https://finnhub.io/api/news?id=fb894cf526206c9268a058014151289ebb260ad7ca553539da921376e35a4fbb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
    "summary": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=f7db3f7c8ded67d2097472772e1eb373ea6980bde18c13ae966df881492a8431",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733934780,
      "headline": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "id": 131932778,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=f7db3f7c8ded67d2097472772e1eb373ea6980bde18c13ae966df881492a8431"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients",
    "summary": "On Wednesday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor. Imlunestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) as monotherapy in patients with an ESR1 mutation versus stand",
    "url": "https://finnhub.io/api/news?id=25d26d90bfa56a6971da471e0ac913581ce413a7b21de613767d8f3c9eef2046",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733934514,
      "headline": "Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients",
      "id": 131941690,
      "image": "https://media.zenfs.com/en/Benzinga/1958e8b1e60ed3cb3842f5579bc06c27",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On Wednesday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor. Imlunestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) as monotherapy in patients with an ESR1 mutation versus stand",
      "url": "https://finnhub.io/api/news?id=25d26d90bfa56a6971da471e0ac913581ce413a7b21de613767d8f3c9eef2046"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Will Sell Zepbound Through Telehealth Company Ro in a Swipe at Legal Copycats",
    "summary": "Amid new worries that legal copycats of the weight-loss drugs from  Eli Lilly  and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound through the telemedicine company Ro.  The privately held Ro is one of the long and growing list of telehealth services prescribing and selling compounded GLP-1 drugs through its online platform.  Under the newly announced arrangement, Ro will prescribe single-dose vials of Zepbound through its online platform that Lilly will fill through LillyDirect, Lilly’s mail-order pharmacy.",
    "url": "https://finnhub.io/api/news?id=1e0e7be5e68c37516ec2dc735c42dc28b650aa34974d80d0c770d3aa9554deab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733933580,
      "headline": "Eli Lilly Will Sell Zepbound Through Telehealth Company Ro in a Swipe at Legal Copycats",
      "id": 131941693,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amid new worries that legal copycats of the weight-loss drugs from  Eli Lilly  and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound through the telemedicine company Ro.  The privately held Ro is one of the long and growing list of telehealth services prescribing and selling compounded GLP-1 drugs through its online platform.  Under the newly announced arrangement, Ro will prescribe single-dose vials of Zepbound through its online platform that Lilly will fill through LillyDirect, Lilly’s mail-order pharmacy.",
      "url": "https://finnhub.io/api/news?id=1e0e7be5e68c37516ec2dc735c42dc28b650aa34974d80d0c770d3aa9554deab"
    }
  },
  {
    "ts": null,
    "headline": "Ro partners with Eli Lilly to expand access to Zepbound vials",
    "summary": "Ro launches access to Eli Lilly's single-dose vials of GLP-1 Zepbound.",
    "url": "https://finnhub.io/api/news?id=c3f21a6d8f30c15c8d8100e241b0018572e15a509a51a76fd4c505a7046f3fd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733928657,
      "headline": "Ro partners with Eli Lilly to expand access to Zepbound vials",
      "id": 131926928,
      "image": "https://s.yimg.com/ny/api/res/1.2/3myG0hiLYXE7Qw0jm8kkcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/2f22fd70-b7c4-11ef-9eaf-16041e48ae9b",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Ro launches access to Eli Lilly's single-dose vials of GLP-1 Zepbound.",
      "url": "https://finnhub.io/api/news?id=c3f21a6d8f30c15c8d8100e241b0018572e15a509a51a76fd4c505a7046f3fd0"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor. Imlunestrant demonstrated a statistically significant and clinically meaningful improve",
    "url": "https://finnhub.io/api/news?id=d128ef439f7704aa526a6880cc4459f2fc29dff2877638cf24841c3e878d69fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733922900,
      "headline": "Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer",
      "id": 131941697,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor. Imlunestrant demonstrated a statistically significant and clinically meaningful improve",
      "url": "https://finnhub.io/api/news?id=d128ef439f7704aa526a6880cc4459f2fc29dff2877638cf24841c3e878d69fd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly is partnering with Ro to make it easier than ever to get Zepbound",
    "summary": "Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound available on telehealth platform Ro. Starting today, consumers can get an online diagnosis, prescription services, and Zepbound vials delivered to straight their homes — all via Ro.",
    "url": "https://finnhub.io/api/news?id=b35123d6cc1943ea348f71c8ad588430fd76616c44c7db14f482569e4257c1a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733922000,
      "headline": "Eli Lilly is partnering with Ro to make it easier than ever to get Zepbound",
      "id": 131941699,
      "image": "https://media.zenfs.com/en/quartz.com/de209dde08e5487c029ae2c18b7a69d6",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound available on telehealth platform Ro. Starting today, consumers can get an online diagnosis, prescription services, and Zepbound vials delivered to straight their homes — all via Ro.",
      "url": "https://finnhub.io/api/news?id=b35123d6cc1943ea348f71c8ad588430fd76616c44c7db14f482569e4257c1a3"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s £279m bet aims to boost UK life sciences sector",
    "summary": "A cornerstone of the investment is the launch of Europe’s first Lilly Gateway Labs.",
    "url": "https://finnhub.io/api/news?id=f8e27f728b9a3d88ad3c7776e74051a0546539bea9700f306aee1f20d712b34d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733914362,
      "headline": "Lilly’s £279m bet aims to boost UK life sciences sector",
      "id": 131941702,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_664142593.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A cornerstone of the investment is the launch of Europe’s first Lilly Gateway Labs.",
      "url": "https://finnhub.io/api/news?id=f8e27f728b9a3d88ad3c7776e74051a0546539bea9700f306aee1f20d712b34d"
    }
  },
  {
    "ts": null,
    "headline": "BenevolentAI restructures; Lilly preps $15B buyback program",
    "summary": "The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.",
    "url": "https://finnhub.io/api/news?id=80d1d039c420d9b837951d34429b37f0156acdd1ad7bd17e9fffb7159d683f48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733913937,
      "headline": "BenevolentAI restructures; Lilly preps $15B buyback program",
      "id": 131923948,
      "image": "https://imgproxy.divecdn.com/EK5xKj0ydykvmwFmBqsauREtdhrHAUsAiyI6JgDkO1s/g:nowe:0:0/c:1207:682/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.",
      "url": "https://finnhub.io/api/news?id=80d1d039c420d9b837951d34429b37f0156acdd1ad7bd17e9fffb7159d683f48"
    }
  },
  {
    "ts": null,
    "headline": "Pioneer Disciplined Growth Fund Q3 2024 Performance And Market Commentary",
    "summary": "Pioneer Disciplined Growth focuses on mispriced quality, sustainable US large-cap companies trading at attractive valuations with the goal of maximizing risk-adjusted returns.",
    "url": "https://finnhub.io/api/news?id=493fd0bb619284450c947ac1c9ba71107fe27b5b2fcffbbe564800c19bec905c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733913660,
      "headline": "Pioneer Disciplined Growth Fund Q3 2024 Performance And Market Commentary",
      "id": 131920481,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305707642/image_1305707642.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pioneer Disciplined Growth focuses on mispriced quality, sustainable US large-cap companies trading at attractive valuations with the goal of maximizing risk-adjusted returns.",
      "url": "https://finnhub.io/api/news?id=493fd0bb619284450c947ac1c9ba71107fe27b5b2fcffbbe564800c19bec905c"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?",
    "summary": "The agency has yet to make a decision about keeping tirzepatide on or off of its shortage list — letting compound pharmacies continue their lucrative operations for now.",
    "url": "https://finnhub.io/api/news?id=7b954cad7adb823c5260a7fdeed70037e6c95efbbfd1594e6d1b4b5fd539ba97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733904000,
      "headline": "GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?",
      "id": 131926929,
      "image": "https://imgproxy.divecdn.com/ix-kZRmab9ximqGrtU4nHdRG0Pchkkv2k6cN0wyaS6o/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9aZXBCb3VuZFYyX0RldmljZUZyb250XzJwdDUucG5n.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The agency has yet to make a decision about keeping tirzepatide on or off of its shortage list — letting compound pharmacies continue their lucrative operations for now.",
      "url": "https://finnhub.io/api/news?id=7b954cad7adb823c5260a7fdeed70037e6c95efbbfd1594e6d1b4b5fd539ba97"
    }
  }
]